NASDAQ:CRSP CRISPR Therapeutics Q3 2026 Earnings Results & Report $49.99 -1.43 (-2.78%) Closing price 04:00 PM EasternExtended Trading$49.85 -0.14 (-0.28%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CRISPR Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 2, 2026. The company reported EPS of -$1.15 versus the -$1.04 consensus estimate, while revenue of $12.67 million fell short of the $14.75 million estimate by $2.08 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 2, 2026TimeAfter Market ClosesConference Call4:00 PM ET CRISPR Therapeutics EPS ResultsActual EPS-$1.15Consensus EPS -$1.04Beat/MissMissed by -$0.11One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCRISPR Therapeutics Revenue ResultsActual Revenue$12.67 millionExpected Revenue$14.75 millionBeat/MissMissed by -$2.08 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CRISPR Therapeutics Q3 2026 Earnings FAQ Did CRISPR Therapeutics beat earnings estimates for Q3 2026? CRISPR Therapeutics (NASDAQ:CRSP) reported earnings of -$1.15 per share for Q3 2026, missing the consensus estimate of -$1.04. The report was announced on Monday, November 2, 2026. What was CRISPR Therapeutics' revenue for Q3 2026? CRISPR Therapeutics reported revenue of $12.67 million for Q3 2026, against a consensus estimate of $14.75 million. CRISPR Therapeutics Earnings HeadlinesCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results3 hours ago | finance.yahoo.comCasgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction3 hours ago | fool.comNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.November 2 at 1:00 AM | Porter & Company (Ad)CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates3 hours ago | finance.yahoo.comCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsNovember 2 at 4:01 PM | globenewswire.comCRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical OfficerNovember 2 at 3:00 PM | finance.yahoo.comSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease. Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. CASGEVY uses CRISPR/Cas9 gene editing to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s blood stem cells before they are returned to the body. The company also maintains a pipeline of investigational therapies, including programs involving immune-cell engineering and gene-edited cell therapies. CRISPR Therapeutics was founded in 2013 based on discoveries involving CRISPR/Cas9 technology. The company has corporate operations in Zug, Switzerland, and Boston, Massachusetts, and works with partners to develop and commercialize therapies for patients in multiple international markets. Samarth Kulkarni, Ph.D., serves as chief executive officer, while scientific founder Emmanuelle Charpentier remains associated with the company’s scientific origins.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings Booking (11/3/2026)Ferrari (11/3/2026)Marathon Petroleum (11/3/2026)Mplx (11/3/2026)Suncor Energy (11/3/2026)Apollo Global Management (11/3/2026)Itau Unibanco (11/3/2026)Amgen (11/3/2026)Pfizer (11/3/2026)Eaton (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
